The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Bariatric Surgery CandidatePain, Postoperative
Interventions
DRUG

Exparel 266 MG Per 20 ML Injection

Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).

DRUG

Bupivacaine

60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).

Trial Locations (1)

93720

Fresno Heart and Surgical Hospital, Fresno

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT03196505 - The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery | Biotech Hunter | Biotech Hunter